May 4, 2015 -- Shanghai Generon Corporation has been granted FDA approval to begin a US Phase IIa clinical trial of its novel recombinant human interleukin. The molecule will be tested as a treatment for graft-versus-host disease in the lower intestines of patients undergoing hematopoietic stem cell transplants, a side-effect with incidence as high as 50%. Generon says the drug offers a treatment alternative that, instead of increasing immune suppression, aims to regenerate the intestines.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
